Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Pembrolizumab in MSI-H Colorectal Cancer
NCT06006923Phase 2Terminated
- Start
- Jun 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in colorectal cancer (CRC). Started Jun 2024; status: terminated.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06006923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006923.